ETON (Eton Pharmaceuticals) Institutional Ownership: 65.64% (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ETON Eton Pharmaceuticals Inc ETON
57 GF Score
Price $58.51
GF Value $19.98
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Eton Pharmaceuticals Institutional Ownership?

Eton Pharmaceuticals ETON +44.55% 57 Institutional Ownership is 65.64% as of Aug. 14, 2026. GuruFocus rates ETON with a GF Score™ of 57/100 and a GF Value™ of $19.98 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Eton Pharmaceuticals's institutional ownership is 65.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Eton Pharmaceuticals's Insider Ownership is 8.46%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Eton Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 71.13%.

Eton Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Eton Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eton Pharmaceuticals Institutional Ownership Chart

Eton Pharmaceuticals Historical Data

The historical data trend for Eton Pharmaceuticals can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 21.54 21.77 21.86 21.59 21.61 22.07 22.34 23.31 25.94 26.69
ETON
57GF Score
Eton Pharmaceuticals Inc ETON
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eton Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 65.64% mean?
Eton Pharmaceuticals (ETON) has a Institutional Ownership of 65.64% as of Aug. 14, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Eton Pharmaceuticals and its competitors.
Is Eton Pharmaceuticals' Institutional Ownership too high?
Eton Pharmaceuticals' current Institutional Ownership is 65.64%. Overall, Eton Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eton Pharmaceuticals' Institutional Ownership compare to COLL and ALVO?
Eton Pharmaceuticals' Institutional Ownership of 65.64% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Eton Pharmaceuticals and its competitors. Eton Pharmaceuticals's current Institutional Ownership is 65.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eton Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Eton Pharmaceuticals (ETON) is currently considered Significantly Overvalued. The stock's GF Value™ is $19.98, compared to a current price of $58.51 — trading 192.8% above its estimated fair value. The current Institutional Ownership is 65.64%. Eton Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Eton Pharmaceuticals (ETON), the current Institutional Ownership is 65.64% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eton Pharmaceuticals (ETON) Overvalued in 2026?

Based on GuruFocus' analysis, Eton Pharmaceuticals stock appears to be overvalued. The current stock price of $58.51 is trading 192.8% above its estimated GF Value™ of $19.98. GuruFocus considers Eton Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ETON:

  • Institutional Ownership: 65.64%
  • GF Value™: $19.98 vs. price of $58.51 (192.8% above fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the ETON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eton Pharmaceuticals Business Description

Address 21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
57GF Score

Get the complete analysis for ETON

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.51
Price
$19.98
GF Value